Timeline of chemotherapy

From Timelines
Jump to navigation Jump to search

This is a timeline of chemotherapy, tracing its emergence from early twentieth-century experimental concepts to modern multimodal cancer treatments. It highlights discoveries, clinical breakthroughs, drug developments, institutional programs, and evolving therapeutic strategies that transformed chemotherapy into a central pillar of oncology, improving survival rates and shaping contemporary cancer care worldwide.

Sample questions

The following are some interesting questions that can be answered by reading this timeline:

Big picture

Time period Development summary More details
Early 1900s–1940s Foundations and Conceptual Origins Early theoretical and experimental groundwork is established. Paul Ehrlich coins “chemotherapy” and promotes chemical therapeutics. Animal tumor models and screening programs emerge, while wartime observations (e.g., nitrogen mustard) reveal cytotoxic effects on rapidly dividing cells.
1940s–1950s Emergence of Systemic Chemotherapy Chemotherapy becomes a clinical reality. First systemic treatments using nitrogen mustard demonstrate temporary remissions. Antifolates (e.g., methotrexate) achieve the first leukemia remissions, while institutional programs such as the National Cancer Institute coordinate drug discovery and screening.
1960s–1970s Combination Therapy and Curative Potential Conceptual breakthroughs transform outcomes. Combination chemotherapy regimens overcome resistance and enable cures in diseases like childhood leukemia and Hodgkin’s disease. The “cell kill hypothesis” and clinical protocols establish chemotherapy as a central, potentially curative modality.
1980s–Present Expansion, Targeting, and Integration Chemotherapy evolves within a broader oncology framework. Advances in molecular biology enable targeted therapies (e.g., imatinib), while combination regimens, adjuvant therapy, and integration with surgery, radiotherapy, and immunotherapy improve survival and reduce mortality globally.

Full timeline

Year Event type Details Geographical location
Early 1900s Development Chemotherapy is first developed, although not initially intended for the treatment of cancer.[1] Multiple (primarily Europe and United States)
Early 20th century Research Initial attempts to treat cancer with chemotherapy begin, focusing on narrowing effective chemical compounds through screening methods using transplantable tumors in rodents.[2]
1900s Concept Paul Ehrlich coins the term chemotherapy and promotes the use of chemicals to treat disease, while pioneering animal models for drug screening.[3] Germany
1908 Medical advance Ehrlich develops arsenical treatments for syphilis using rabbit models, establishing proof of concept for chemical therapeutics.[3] Germany
Early 1910s Model development George Clowes develops the first transplantable tumor systems in rodents at Roswell Park, enabling standardized cancer drug screening.[3] United States
1929 Clinical use Early local chemotherapy is applied by Adair and Bagg in a small group of patients, marking one of the first therapeutic uses of chemical agents against cancer.[4] United States
1930s Controversy Cornelius P. Rhoads writes a racist letter alleging harmful experimentation in Puerto Rico; subsequent investigations absolve him and the incident is managed through public relations efforts.[4] Puerto Rico / United States
1935 Research program Murray Shear establishes an organized cancer drug screening program, testing thousands of compounds using murine tumor models.[3] United States
1937 Discovery Folic acid is synthesized, later becoming central to antifolate chemotherapy development.[3] United States
1937 Institution Shear’s program becomes associated with the National Cancer Institute following institutional consolidation.[3] United States
1939 Appointment Rhoads becomes Director of the Memorial Hospital for the Treatment of Cancer and Allied Diseases.[4] United States (New York)
1939 Medical advance Charles Huggins demonstrates hormonal therapy effectiveness in prostate cancer, introducing systemic cancer treatment approaches.[3] United States
1940s Discovery During World War II, exposure to nitrogen mustard is observed to reduce white blood cell counts, suggesting potential effects on rapidly dividing cells.[1] Multiple (wartime research contexts)
1940s Research program World War II–related research programs lead to the discovery of anticancer properties in certain chemical agents, laying the groundwork for modern chemotherapy.[2]
1942 Clinical milestone The first systemic chemotherapy treatment is administered (patient “JD”), marking the beginning of systemic anticancer drug therapy.[4] United States
May 1942 Clinical use Louis Goodman and Alfred Gilman, with Gustav Linskog, administer nitrogen mustard (azotiprites) to a lymphoma patient, achieving a temporary remission.[5] United States (Yale School of Medicine)
1943 Experiment Alfred Gilman and Louis Goodman, along with Gustav Linskog, conduct early clinical experiments using mustine (nitrogen mustard) to treat non-Hodgkin lymphoma, demonstrating temporary tumor reduction.[1] United States (Yale University)
1943 Breakthrough Alfred Gilman and Louis Goodman demonstrate antitumor effects of nitrogen mustard in lymphoma patients.[3] United States
1945 Institutional founding Rhoads secures funding from Alfred P. Sloan and Charles F. Kettering to establish the Memorial Sloan Kettering Cancer Center, advancing organized cancer research and chemotherapy development.[4] United States (New York)
1945 Historical context The atomic bombing of Hiroshima occurs on August 6, the same date sometimes incorrectly associated with key chemotherapy developments.[4] Japan
1940s Drug introduction Introduction of nitrogen mustard and antifolate drugs marks the beginning of modern cancer chemotherapy.[6] United States
Post-1945 Advocacy Rhoads promotes chemotherapy for cancer, drawing on prior work with mustard gas and contributing to institutional and financial support for the field.[4] United States
1946 Publication Results of nitrogen mustard treatment studies are published, leading to broader adoption of alkylating agents in cancer therapy.[1] United States
1946 Publication Clinical results of nitrogen mustard therapy are published, generating optimism about chemotherapy.[3] United States
1947 Breakthrough First partial remission in leukemia is achieved using aminopterin, demonstrating the potential of antifolate chemotherapy.[5] United States (Boston Children's Hospital)
Late 1940s Drug class Nitrogen mustard and related compounds are classified as alkylating agents, capable of damaging DNA, RNA, and proteins to inhibit cancer cell growth.[1] United States and Europe
Late 1940s Research Sidney Farber investigates folates and develops antifolate drugs such as methotrexate, capable of suppressing cancer cell proliferation.[5] United States
Late 1940s Drug discovery Antibiotic screening programs identify antitumor agents such as actinomycin D.[3] United States
1948 Breakthrough Sidney Farber and colleagues demonstrate that antifolates such as methotrexate can induce remission in children with acute lymphoblastic leukemia, marking the first successful chemotherapy-induced remissions.[1] United States (Harvard Medical School)
1948 Drug development Gertrude Elion and George Hitchings develop thiopurines (e.g., 6-mercaptopurine) for leukemia treatment.[3] United States
1948 Medical advance Sidney Farber demonstrates leukemia remission using antifolates (e.g., methotrexate), marking a major milestone in pediatric oncology.[3] United States
Early 1950s Screening Leukemia L1210 model emerges as a key system for predicting anticancer drug activity.[3] United States
1953 Program closure Shear’s screening program is dissolved due to limited clinical success and toxicity concerns.[3] United States
1955 Program The Cancer Chemotherapy National Service Center (CCNSC) is established at the National Cancer Institute to coordinate drug discovery and development.[5] United States
1955 Program The Cancer Chemotherapy National Service Center (CCNSC) is established at the National Cancer Institute to coordinate drug discovery and development.[4] United States
1955 Institution Establishment of the Cancer Chemotherapy National Service Center, initiating a coordinated national drug development effort in the United States.[2]
1955 Institution Establishment of the Cancer Chemotherapy National Service Center (CCNSC), launching a coordinated national drug development program.[3] United States
1956 Drug discovery C. Gordon Zubrod promotes large-scale screening of natural products, leading to discovery of key drug classes including taxanes (e.g., paclitaxel) and camptothecins.[5] United States
1956 Drug discovery C. Gordon Zubrod promotes large-scale screening of natural products, leading to discovery of key drug classes including taxanes (e.g., paclitaxel) and camptothecins.[4] United States
1958 Drug introduction 5-fluorouracil (5-FU) enters clinical use as a treatment for solid tumors.[3] United States
1950s Program The Cancer Chemotherapy National Service Center (CCNSC) is established, creating a centralized system for drug screening, development, and clinical testing that later underpins the modern cancer pharmaceutical industry.[7] United States (National Cancer Institute)
1950s Discovery Eli Lilly and Company identifies anticancer properties in plant alkaloids derived from Vinca rosea, showing effectiveness against leukemia.[1] United States
1960 Model system The L1210 leukemia system is established as a primary experimental model for screening drugs and studying treatment strategies for acute leukemia.[7] United States
Early 1960s Clinical context Chemotherapy faces strong resistance in clinical medicine; anticancer drugs are widely viewed as toxic “poisons,” and medical oncology is not yet recognized as a specialty.[7] United States
1960s Medical advance Development of combination chemotherapy demonstrates curative potential in acute childhood leukemia, challenging prior pessimism about drug-based cancer treatment.[2]
1960s Medical advance combination chemotherapy demonstrates curative potential in acute childhood leukemia.[3] United States
1960s Experimental insight Frank Schabel and Howard Skipper demonstrate that combination chemotherapy prevents resistance and that drugs kill a fraction of cancer cells rather than a fixed number.[5] United States (Southern Research Institute)
1960s Drug introduction Vinca alkaloids such as vinblastine and vincristine are introduced as chemotherapy agents for Hodgkin's disease and pediatric leukemia.[1] United States
1960s Experimental insight Frank Schabel and Howard Skipper demonstrate that combination chemotherapy prevents resistance and that drugs kill a fraction of cancer cells rather than a fixed number.[4] United States (Southern Research Institute)
1964 Preclinical breakthrough Howard Skipper reports the first cure of L1210 leukemia in mice and formulates the “cell kill hypothesis,” demonstrating that chemotherapy kills a constant fraction of tumor cells.[7] United States (Southern Research Institute)
1965 Clinical results Early results of combination chemotherapy for Hodgkin's disease (MOMP regimen) are presented, showing major improvements in remission rates.[7] United States (National Cancer Institute)
1965 Discovery Cisplatin is discovered by Barnett Rosenberg, later becoming a major anticancer drug.[5] United States
1967 Clinical results The MOPP regimen (including procarbazine) is presented, demonstrating high complete remission rates in advanced Hodgkin’s disease.[7] United States (NCI)
1960s Treatment paradigm Recognition of micrometastasis leads to integration of chemotherapy with surgery and radiotherapy.[3] United States
1960s–1970s Treatment strategy Combination chemotherapy regimens, using multiple drugs with different mechanisms, become widely adopted, improving survival rates.[1] Global (initially United States and Europe)
Mid-1960s Regimen development Combination chemotherapy protocols such as VAMP (vincristine, methotrexate, 6-mercaptopurine, prednisone) are introduced, significantly increasing remission rates in childhood leukemia.[7] United States (multiple institutions including NCI, St. Jude, Boston Children’s)
1965 Discovery Cisplatin is discovered by Barnett Rosenberg, later becoming a major anticancer drug.[4] United States
Circa 1968 Innovation Min Chiu Li develops curative chemotherapy approaches for metastatic choriocarcinoma and testicular cancer.[7] United States (Memorial Sloan Kettering Cancer Center)
1970 Publication Results of MOPP chemotherapy are published, establishing chemotherapy as a curative treatment for advanced Hodgkin’s disease in adults.[7] United States
1970 Outcome By this time, a significant fraction of childhood leukemia cases are considered curable through combination chemotherapy. Global (led by U.S. institutions)
Early 1970s Medical advance Combination chemotherapy achieves cures in advanced Hodgkin's disease, reinforcing drug-based cancer treatment.[3] United States
1970s Treatment strategy The concept of adjuvant chemotherapy emerges, applying chemotherapy after surgery or radiotherapy to eliminate micrometastases. United States and Europe
1970s Research expansion Successes in chemotherapy facilitate the development and study of adjuvant chemotherapy and contribute to the growth of the national cancer program.[2]
1970s Clinical strategy Development of adjuvant chemotherapy and combined modality treatment becomes standard clinical practice.[3] United States
1971 Policy The National Cancer Act is passed, expanding federal support for cancer research and enabling the creation of new cancer centers.[7] United States
1972 Award The Lasker Award is granted to key researchers demonstrating that chemotherapy can cure cancer; C. Gordon Zubrod is recognized for program leadership.[7] United States
1973 Institutionalization Medical oncology is formally established as a subspecialty of internal medicine, with chemotherapy as a central tool.[7] United States
1974 Clinical research Lawrence Einhorn begins studies using combination chemotherapy (cisplatin, vinblastine, bleomycin), dramatically improving survival in metastatic testicular cancer.[7] United States
1974 Clinical adoption The FAC regimen (fluorouracil, doxorubicin, and cyclophosphamide) enters clinical use as an anthracycline-containing adjuvant chemotherapy for resectable breast cancer, with studies indicating strong efficacy and establishing doxorubicin as a key agent in treatment. [8] United States
1975 Clinical advance Cure of advanced diffuse large B-cell lymphoma is reported using the C-MOPP regimen.[7] United States (NCI)
1975 Trial result L-PAM adjuvant chemotherapy trial shows benefit in breast cancer and is published in the New England Journal of Medicine.[7] United States
1975 Clinical modification Variants of the CMF regimen (cyclophosphamide, methotrexate, fluorouracil) introduce oral and intravenous cyclophosphamide administration schedules, demonstrating comparable efficacy while offering flexibility in treatment delivery and patient management. [9] Italy
1976 Trial result CMF adjuvant chemotherapy trial led by Gianni Bonadonna demonstrates effectiveness in breast cancer.[7] Italy (Istituto Nazionale Tumori)
1976 Clinical trial The CMF regimen (cyclophosphamide, methotrexate, and fluorouracil) is established as an effective adjuvant chemotherapy for resectable breast cancer, demonstrating improved outcomes and becoming a standard postoperative treatment. [10] Italy
1978 Clinical trial / regimen introduction Early clinical studies demonstrate the efficacy of the combination of cyclophosphamide, doxorubicin, and vincristine (CAV) in small-cell lung cancer, showing complete remissions, acceptable toxicity, and improved survival. The regimen becomes one of the first standard chemotherapy treatments for small-cell lung cancer and is administered in the outpatient setting, often combined with concurrent radiation therapy in patients with limited disease. [11] United States
Late 1970s Breakthrough Cure rates for metastatic testicular cancer rise from ~10% to ~60% due to combination chemotherapy. United States
1978–1979 Clinical adoption Cisplatin becomes a key treatment for testicular cancer; carboplatin is later developed as a less toxic derivative.[5] United States / United Kingdom
1984 Outcome National mortality from childhood leukemia and Hodgkin’s disease declines by approximately 65% due to adoption of chemotherapy.[7] United States
1984 Clinical trial / regimen development Clinical studies report the use of the combination of cyclophosphamide, doxorubicin (Adriamycin), and etoposide (CAE/ACE) in extensive-stage small-cell lung cancer. Developed in the early 1980s, this regimen combines three of the most active agents available at the time and demonstrates efficacy in advanced disease, contributing to its continued clinical use as a multi-agent chemotherapy approach. [12] United States
1985 Clinical trial A study reports that neoadjuvant chemotherapy with fluorouracil (120-hour infusion) plus cisplatin significantly improves complete response rates and survival in advanced head and neck cancer, achieving an overall response rate of 93% and demonstrating superiority over competing regimens. [13] United States
1986 Clinical trial The fluorouracil, doxorubicin, and methotrexate (FAMTX) regimen is introduced and evaluated for metastatic gastric cancer, showing improved response rates compared to earlier regimens such as FAM, with an overall response rate of about 59% and establishing FAMTX as a standard chemotherapy option in advanced disease. [14]
1986 Clinical trial The combination of streptozotocin, mitomycin, and fluorouracil (SMF) is evaluated for advanced pancreatic cancer, showing modest response rates comparable to other multi-agent regimens and illustrating early efforts to improve outcomes beyond single-agent fluorouracil therapy. [15]
1987 Clinical trial A phase II study evaluates intensive-dose doxorubicin as a single-agent salvage therapy for metastatic breast cancer, confirming its activity in previously treated patients despite limited durability of responses and notable cardiotoxicity risks. [16]
1987–1994 Clinical trials / regimen comparison Clinical studies evaluate etoposide plus carboplatin (VP-CP) for small-cell lung cancer, showing it is at least as active as etoposide plus cisplatin (VP-P/EC) while producing less nonhematologic toxicity. In one early study, VP-CP combined with thoracic irradiation (and prophylactic cranial irradiation in complete responders) achieves objective response rates of 77% in limited disease and 58% in extensive disease, with complete responses of 40% and 9%, respectively, and median relapse-free survival of 14.6 months (limited disease) and 7.9 months (extensive disease). Subsequent randomized trials confirm that carboplatin- and cisplatin-based regimens are equally active when combined with etoposide, but carboplatin is associated with a more favorable toxicity profile, including less nausea, vomiting, and mucositis, despite higher rates of hematologic toxicity such as neutropenia.
1980s Research focus Expansion of cytotoxic drug discovery alongside increasing use of molecular and genetic approaches to understand tumor biology.[4] Global
1980s Research focus Expansion of cytotoxic drug discovery alongside increasing use of molecular and genetic approaches to understand tumor biology.[5] Global
1989 Clinical trial The AC regimen (doxorubicin and cyclophosphamide) is introduced as an effective adjuvant chemotherapy for resectable breast cancer, demonstrating comparable efficacy with fewer treatment cycles than CMF regimen and improving tolerability and convenience. [17] United States
1989 Clinical trial The etoposide, doxorubicin, and cisplatin (EAP) regimen is evaluated in advanced gastric cancer, demonstrating a high overall response rate (around 64%) and significant complete responses, establishing EAP as a highly active but toxic combination chemotherapy option compared to earlier regimens. [18]
1990 Clinical trial The etoposide, leucovorin, and fluorouracil (ELF) regimen is evaluated for metastatic gastric cancer, demonstrating substantial activity with an overall response rate of about 52% and improved tolerability compared to more toxic regimens such as EAP, making it a suitable option for older or frail patients. [19]
1990 Clinical guideline / second-line therapy Cyclophosphamide or chlorambucil are established as standard second-line treatments for chronic lymphocytic leukemia, particularly in patients with progressive or symptomatic disease, reinforcing the role of alkylating agents for disease control and symptom relief rather than curative intent. [20]
1990–1991 Clinical practice / regimen use Combination chemotherapy with etoposide and cisplatin (VP) is used in metastatic non-small cell lung cancer, reflecting broader adoption of cisplatin-based regimens in advanced disease. While evidence supports activity, there is no consensus on a standard regimen, and debate persists regarding the overall benefit of combination chemotherapy. In clinical practice, treatment is considered reasonable for selected patients with good performance status, low tumor burden, and minimal weight loss. Typically, only two to three cycles are recommended in non-responders. This period highlights a transitional phase in NSCLC management, characterized by heterogeneity in regimen selection and uncertainty regarding optimal therapy. [21] [22] Not specified
1990–present Outcome trend Cancer mortality rates decline steadily due to advances in early detection and the increasing effectiveness of chemotherapy treatments.[1] Global
1990 Clinical trial The PCV regimen (procarbazine, lomustine [CCNU], and vincristine) demonstrates improved survival and longer time to tumor progression compared to single-agent carmustine (BCNU) when used as adjuvant chemotherapy following surgery and radiotherapy in anaplastic gliomas. [23] United States
1990 Clinical trial Combination adjuvant chemotherapy with fluorouracil and levamisole demonstrates significant survival benefit in resected stage III colon cancer, establishing a new standard of care for postoperative treatment and marking a major advance in colorectal cancer management. [24]
1991 Clinical trial A randomized trial shows that idarubicin combined with cytarabine improves overall survival compared to daunorubicin plus cytarabine in adult acute myelogenous leukemia, with median survival of 19.5 months versus 13.5 months, supporting idarubicin-based regimens as a new standard induction therapy. [25] United States
1991 Clinical trial / regimen intensification Clinical studies introduce the CODE regimen, a dose-dense combination of cisplatin, vincristine, doxorubicin, and etoposide for extensive-stage small-cell lung cancer. Rather than increasing individual drug doses, the regimen intensifies therapy by shortening intervals between cycles, resulting in high cumulative dose intensity and limiting tumor regrowth between treatments. In clinical evaluation, CODE achieves an overall response rate of 94%, including 40% complete remissions. However, the regimen is associated with substantial toxicity, including a high risk of severe adverse effects and prolonged hospitalizations compared with standard regimens. Effective management requires comprehensive supportive care (e.g., corticosteroids, antimicrobial prophylaxis), highlighting the trade-off between efficacy and tolerability in dose-intensified chemotherapy strategies. [26] Canada
1991 Clinical trial A phase II study evaluates a combination chemotherapy regimen of mitoxantrone, fluorouracil, and leucovorin (NFL) for metastatic breast cancer, demonstrating activity with relatively manageable toxicity and supporting its use as an alternative to doxorubicin-based regimens. [27]
1991 Clinical trial Intensive combination chemotherapy using prednisone, vincristine, and daunorubicin demonstrates improved complete remission rates (70–80%) in adult acute lymphoblastic leukemia, compared to ~45% with vincristine and prednisone alone, supporting the addition of anthracyclines in induction therapy. [28] United States
1991 Clinical trial The etoposide, fluorouracil, and cisplatin (EFP) regimen is evaluated as neoadjuvant and adjuvant therapy for locoregional (potentially curable) gastric cancer, demonstrating substantial tumor response and a 72% curative resection rate in early studies, supporting its use in perioperative treatment strategies. [29]
1991 Clinical trial Combined chemoradiation using fluorouracil and mitomycin (FUM regimen) demonstrates high efficacy in anal cancer, achieving complete response rates of 84% and 5-year survival of 72% in primary tumors, supporting combined-modality therapy as standard treatment. [30] Norway
1991 Clinical trial fluorouracil (5-FU) is evaluated as a single-agent chemotherapy for advanced pancreatic cancer, confirming limited efficacy and establishing it as a baseline treatment option, with studies showing that combination with leucovorin does not significantly improve outcomes over fluorouracil alone. [31]
1991–1992 Clinical trials / regimen standardization Randomized trials demonstrate that the combination of etoposide and cisplatin (VP-P) achieves efficacy comparable to older regimens such as cyclophosphamide, doxorubicin, and vincristine (CAV), with reduced toxicity. Four cycles of VP-P show equivalent activity to six cycles of CAV. The regimen produces overall response rates exceeding 80% in limited small-cell lung cancer, including complete responses of 30%–40%, and response rates exceeding 60% in extensive disease, with complete responses of 20%–25%. VP-P is consequently regarded as a standard, less toxic alternative in small-cell lung cancer. [32] [33]
1992 Clinical trial Combined-modality therapy using cisplatin and fluorouracil (C/5-FU) with radiotherapy is evaluated for localized esophageal cancer, demonstrating improved survival compared to radiotherapy alone, albeit with increased toxicity, supporting the adoption of chemoradiation as a standard approach. [34]
1992 Therapeutic breakthrough The introduction of single-agent cladribine (2-CdA) demonstrates very high response rates (approaching ~95%, including ~80% complete remissions) in hairy cell leukemia, establishing it as the treatment of choice and leading to a decline in the use of splenectomy as standard therapy. [35]
1992 Clinical trial Prospective randomized trial shows that hepatic arterial infusion of floxuridine improves survival in patients with liver metastases from colorectal cancer, achieving a median survival gain of approximately 4 months and higher 1- and 2-year survival rates compared with systemic therapy or supportive care, supporting regional chemotherapy approaches. [36]
1993 Clinical trial Preoperative combined-modality therapy using cisplatin, vinblastine, and fluorouracil (CVF) with concurrent radiotherapy is evaluated for locoregional esophageal cancer, showing improved resectability and survival outcomes compared to surgery alone, supporting neoadjuvant chemoradiation strategies. [37]
1993 Clinical trial / therapeutic strategy A randomized study establishes hydroxyurea as superior to busulfan in chronic myelogenous leukemia, leading to its adoption as first-line cytoreductive therapy. Clinical use includes titration based on white blood cell counts, initiation at leukocytosis (>50,000/μL), and application as a temporizing treatment in chronic and accelerated phases, with transition to acute leukemia regimens upon blast transformation. [38]
1993 Clinical study / therapeutic shift Studies establish fludarabine (with or without prednisone) as an effective first-line therapy for chronic lymphocytic leukemia, demonstrating substantial overall and complete response rates in both previously treated and untreated patients, and contributing to the transition away from alkylating-agent–based regimens such as cyclophosphamide or chlorambucil. [39] [40]
1993 Clinical study / palliative single-agent chemotherapy Vinorelbine, a semi-synthetic vinca alkaloid, is evaluated as a single-agent therapy for patients with advanced, unresectable non-small cell lung cancer. Administered intravenously on a weekly schedule, vinorelbine demonstrates palliative efficacy with median survival comparable to combination regimens such as vindesine plus cisplatin, but with substantially reduced toxicity, particularly less neurotoxicity. While combination therapy (vinorelbine plus cisplatin) achieves longer survival, it is associated with higher toxicity. Single-agent vinorelbine emerges as a valuable palliative option, offering a favorable balance between efficacy and tolerability and supporting its use in patients where quality of life is a primary consideration. [41] Not specified
1993 Clinical study / palliative regimen A study by Keane and Carney evaluates single-agent oral etoposide (poV) as palliative therapy for elderly patients with small-cell lung cancer, including both limited and extensive disease. The regimen shows substantial activity, with an overall response rate of 76%, median survival of 38 weeks, and a 2-year survival rate of 10%. Outcomes are comparable to more intensive regimens but with reduced need for hospitalization. Oral etoposide is associated with improved quality of life, minimal morbidity, and low treatment-related mortality, supporting its use as a practical, less intensive option in older or frail patients. [42] Not specified
1993 Clinical study / oral chemotherapy regimen An all-oral chemotherapy regimen combining etoposide and cyclophosphamide (poVC) is evaluated for patients with stage IV non-small cell lung cancer. The regimen delivers both drugs orally over days 1–14 in 28-day cycles. In clinical evaluation, poVC shows modest activity, achieving an overall response rate of 12%, with a median survival of approximately 6 months and a 1-year survival rate of 26%. Compared with cisplatin-based regimens, toxicity is milder and the treatment is better tolerated. Although less effective than standard intravenous combinations, poVC offers advantages in convenience, reduced cost, and improved quality of life, making it a reasonable palliative option for advanced disease. [43] Not specified
1993 Clinical trial Neoadjuvant chemotherapy using carmustine (BCNU) and cisplatin prior to radiotherapy shows improved outcomes in high-grade astrocytoma, with Phase II trials reporting 1-year survival of 64% and overall response rates up to 70%, supporting the benefit of pre-radiation chemotherapy over conventional approaches. [44][45] United States
Early 1990s Clinical study FAC regimen (fluorouracil, doxorubicin, cyclophosphamide) is applied as neoadjuvant chemotherapy for locally advanced breast cancer, demonstrating high tumor response rates (≈90% regression) and enabling tumor downstaging to allow breast-conserving surgery. [46][47] United States
Early 1990s Clinical study A modified “3-week” CMF regimen (cyclophosphamide, methotrexate, fluorouracil) demonstrates similar efficacy to the conventional 4-week regimen in adjuvant treatment of resectable breast cancer, with reduced toxicity and improved dose intensity, supporting shorter-duration chemotherapy strategies. [48] Italy
1990s Paradigm shift Emergence of targeted therapy, aiming to direct drugs toward specific molecular targets in cancer cells.[5] Global
1990s Clinical practice Carmustine (BCNU) is used as a single-agent and adjuvant chemotherapy for high-grade malignant gliomas, often combined with radiotherapy; however, evidence shows combination regimens (e.g., CCNU, procarbazine, vincristine) achieve superior outcomes compared to BCNU alone, reinforcing the shift toward multi-agent therapy. [49][50][51] United States
1994 Drug development Imatinib (Gleevec/Glivec) is developed as a targeted therapy.[5] Global
1994 Randomized clinical trial / regimen comparison A three-arm randomized trial evaluates vinorelbine plus cisplatin (NP) versus other cisplatin-based combinations in metastatic non-small cell lung cancer. The NP regimen demonstrates superior outcomes, with improved objective response rate, longer median survival, and higher 1-year survival compared to alternative regimens. The benefit is particularly notable in patients with stage IV disease. However, treatment is associated with increased hematologic toxicity, including a significantly higher incidence of granulocytopenia. These findings contribute to establishing vinorelbine–cisplatin as one of the more effective platinum-based doublets in advanced NSCLC during the early 1990s. [52] Europe
1994 Clinical study / neoadjuvant chemotherapy A combination regimen of mitomycin, ifosfamide, and cisplatin (MIP) is evaluated as preoperative (neoadjuvant) chemotherapy in patients with potentially resectable stage IIIA non-small cell lung cancer. In a randomized trial, preoperative chemotherapy plus surgery significantly improves outcomes compared with surgery alone, increasing median overall survival from 8 to 26 months and disease-free survival from 5 to 20 months. Recurrence rates are also reduced (56% vs 74%). These results provide early evidence supporting neoadjuvant chemotherapy as a strategy to improve surgical outcomes in locally advanced NSCLC, although further studies are required before routine adoption. [53] Not specified
1994 Clinical trial Postoperative chemoradiation combining fluorouracil with pelvic radiation therapy demonstrates reductions in local recurrence and improvements in survival in stage II–III rectal cancer, supporting combined-modality adjuvant therapy. [54] United States
1994 Clinical adoption The FAC regimen (fluorouracil, doxorubicin, cyclophosphamide) is widely established as an anthracycline-containing adjuvant chemotherapy for resectable breast cancer, with accumulated clinical evidence confirming its efficacy and reinforcing doxorubicin as a key therapeutic agent. [55] United States
1994 Clinical study Combination chemotherapy with cisplatin and fluorouracil (C/5-FU) is evaluated for advanced esophageal cancer, demonstrating meaningful response rates—particularly in squamous cell carcinoma—and becoming a commonly used regimen, often combined with radiotherapy despite limited survival gains. [56]
1994 Clinical trial / immunotherapy Randomized studies show that interferon alfa is superior to busulfan and comparable or superior to hydroxyurea in chronic myelogenous leukemia, producing higher cytogenetic response rates, delaying disease progression, and prolonging overall survival, marking a shift toward biologically targeted therapy despite limitations in tolerability and administration. [57] [58] Italy
1994 Clinical trial Randomized comparison of two schedules of fluorouracil plus leucovorin in advanced (metastatic) colorectal cancer finds comparable efficacy between regimens, contributing to the establishment of FUFA as a standard palliative chemotherapy approach. [59] United States
1994 Clinical trial Postoperative chemoradiation combining fluorouracil with pelvic radiation therapy demonstrates significant reductions in recurrence and improved survival in stage II–III rectal cancer, supporting the adoption of combined-modality adjuvant therapy. [60] United States
1994 Clinical trial Combination chemotherapy with fluorouracil and leucovorin (FUFA) demonstrates improved event-free and overall survival in resected stage III colorectal cancer, based on pooled analyses of randomized trials, supporting its adoption as an effective adjuvant therapy. [61]
1994–1995 Clinical trial / regimen intensification A randomized phase III trial by the Hoosier Oncology Group (HOG) evaluates the addition of ifosfamide to standard etoposide–cisplatin (VP), creating the VIP regimen (etoposide, ifosfamide, cisplatin) for extensive-stage small-cell lung cancer. The study population reflects advanced, community-level disease, with many patients having multiple metastatic sites and reduced performance status. While response rates and treatment-related mortality are similar between VIP and VP, hematologic toxicity is significantly greater with VIP. Long-term outcomes show a modest survival advantage for VIP (2-year survival ~12% vs 5%; 3-year ~5% vs 0%), particularly at the tail of the survival curve. Due to increased toxicity and risk of granulocytopenic complications, VIP is not adopted as standard first-line therapy but is considered an aggressive second-line option for selected patients able to tolerate intensive treatment. [62] [63] United States
1995 Clinical trial Sequential chemotherapy using doxorubicin followed by the CMF regimen (A→CMF) demonstrates long-term efficacy in adjuvant treatment of breast cancer, particularly in patients with multiple positive lymph nodes, supporting the strategy of combining anthracycline-based and CMF regimens. [64] Italy
1995 Clinical study / combined modality therapy Weekly paclitaxel administered concurrently with thoracic radiation therapy (T + XRT) is evaluated in patients with locally advanced (stage III), inoperable non-small cell lung cancer. In a phase II study, this combined modality regimen demonstrates a high overall response rate of approximately 84%, with toxicity appearing lower than cisplatin-based chemoradiation approaches. Paclitaxel is given early in the week prior to irradiation, and treatment can be delivered safely in the outpatient setting, although esophagitis emerges as the principal toxicity. These findings support concurrent chemoradiotherapy as an effective strategy in locally advanced NSCLC, while highlighting paclitaxel as a potentially less toxic alternative radiosensitizing agent. [65] Not specified
1995 Clinical trial / regimen development A phase II multi-institutional trial evaluates the combination of paclitaxel and carboplatin (PC) in previously untreated advanced (stage IIIB/IV) non-small cell lung cancer. The regimen demonstrates strong activity, with an overall response rate of 62% (including 9% complete responses) and a 1-year survival rate of 51%, comparing favorably with standard therapies. Responses are observed across disease sites and are often durable, with many lasting over one year. Median progression-free survival is approximately 6 months, and most patients tolerate therapy well, completing all planned cycles. Subsequent institutional studies confirm similar results, with overall response rates around 50% and 1-year survival rates of 37%–54%, establishing paclitaxel plus carboplatin as one of the most active regimens for advanced NSCLC, particularly in stage IV populations. [66] United States
1995 Clinical trial Combination chemotherapy using paclitaxel and doxorubicin demonstrates high antitumor efficacy in metastatic breast cancer, contributing to the integration of taxanes into standard chemotherapy regimens. [67] Italy
1995 Phase II study / regimen optimization A refined outpatient regimen of paclitaxel and carboplatin (PC) is evaluated in previously untreated stage IV non-small cell lung cancer, using higher-dose paclitaxel (≈225 mg/m² over 3 hours) with carboplatin (AUC 7). The combination demonstrates substantial activity, with response rates around 50% in measurable disease and confirmation that full single-agent doses can be safely combined at near-maximal intensity. Parallel studies using shorter infusion schedules (e.g., 1-hour paclitaxel with carboplatin AUC 6) report comparable efficacy. Across studies, overall response rates range from 37% to 54%, with median survival reaching ≥1 year. The regimen is well suited for outpatient administration, balancing efficacy, tolerability, and logistical feasibility, and contributes to establishing paclitaxel–carboplatin as a leading standard doublet in advanced NSCLC. [68] [69] Not specified
1995 Clinical trial / regimen modification Clinical studies evaluate a regimen combining carboplatin, paclitaxel, and etoposide (CPE) for small-cell lung cancer, integrating paclitaxel into platinum-based chemotherapy. The regimen is designed for outpatient administration and is generally well tolerated. In one study, patients with limited and extensive disease receive concurrent radiation (4,500 cGy/25 fractions) beginning with the third cycle of chemotherapy; among 22 evaluable patients, 45% achieve a complete response. Dose escalation of paclitaxel (up to 200 mg/m² via 1-hour infusion) is feasible, though further experience is required before routine adoption. [70] United States
1995 Clinical trial / second-line regimen A phase II trial by the Hoosier Oncology Group evaluates a modified VIP regimen using daily oral etoposide combined with ifosfamide and cisplatin (poVIP) for previously treated, recurrent small-cell lung cancer. The regimen demonstrates substantial activity, with an objective response rate of 55% (including 14% complete responses). Median progression-free survival is 20 weeks and median overall survival is 29 weeks. However, toxicity is considerable, with significant myelosuppression and multiple treatment-related deaths due to sepsis. Despite this, outcomes are considered competitive with many first-line regimens, supporting poVIP as an active but intensive second-line option. [71] United States
1995 Clinical trial A trial by the Eastern Cooperative Oncology Group finds that single-agent paclitaxel achieves an overall response rate of 40% in advanced head and neck cancer, supporting its role as a highly active agent in recurrent/metastatic disease. [72] United States
1995 Combination therapy / clinical study The introduction of all-trans retinoic acid (ATRA) combined with daunorubicin and cytarabine demonstrates high complete remission rates (up to ~80%) in acute promyelocytic leukemia, reducing bleeding-related mortality by inducing leukemic cell differentiation rather than cytotoxic destruction, and establishing ATRA-based combination therapy as standard treatment. [73] Europe
1995 Clinical trial Paclitaxel is evaluated as a single-agent therapy for anthracycline-resistant metastatic breast cancer, with phase II studies demonstrating significant antitumor activity and supporting its role as an effective salvage treatment option following prior doxorubicin-based therapy. [74]
1995 Clinical study / multimodal chemoradiotherapy intensification A complex multimodal regimen combining paclitaxel, cisplatin, and etoposide with concurrent thoracic radiation therapy (PCE + XRT + PCE) is evaluated in patients with locally advanced, unresectable non-small cell lung cancer. The treatment consists of induction chemotherapy (paclitaxel, cisplatin, etoposide), followed by concurrent radiation (6,000 cGy over 30 fractions) with additional chemotherapy, and subsequent consolidation cycles. In clinical evaluation, 58% of evaluable patients achieved partial responses after initial therapy. Among 15 evaluable patients completing treatment, 8 achieved complete or near-complete remission (53%) and 5 had partial responses (33%), yielding an overall response rate of 86%. The regimen is described as highly active and well tolerated in this setting, though still investigational and requiring further study before routine adoption. [75] Not specified
1999 Regulatory approval Food and Drug Administration approves imatinib for treatment of chronic myeloid leukemia.[4] United States
1999 Regulatory approval Food and Drug Administration approves imatinib for treatment of chronic myeloid leukemia.[5] United States
2000s Research focus Increased emphasis on targeting tumor survival mechanisms, including pathways supporting growth and resistance.[4] Global
Late 20th century–present Innovation Shift toward targeted therapy and molecularly guided drug development, using specific genetic and molecular abnormalities to design and screen new cancer treatments.[2]
Late 20th century Paradigm shift Transition toward molecular and biochemical targeting in drug development begins.[3] Global
Late 20th century Clinical role Chemotherapy becomes a central modality in cancer treatment, widely used as both primary and auxiliary therapy across multiple cancer types. [6] Global
Late 20th century Limitation Recognition that single-agent chemotherapy often leads to drug resistance and tumor recurrence due to pathway overlap and biological complexity. [6] Global
Late 20th century Therapeutic shift Emergence of combination chemotherapy as a standard approach to improve efficacy and overcome resistance mechanisms. [6] Global
Late 20th century Treatment principle Establishment of key principles of combination chemotherapy, including non-overlapping toxicity, non-cross resistance, and enhanced tumor cell killing. [6] Global
Late 20th century Drug regimen Development of major chemotherapy combinations such as methotrexate-, anthracycline-, and paclitaxel-based regimens. [6] Global
Late 20th century Mechanism Identification of mechanisms of action of key drugs, including DNA crosslinking by cyclophosphamide and thymidylate synthase inhibition by 5-fluorouracil. [6] Global
Late 20th century Clinical application Adoption of combination regimens such as paclitaxel with cisplatin or carboplatin for advanced ovarian and lung cancers. [6] Global
21st century Innovation Use of molecular abnormalities to guide targeted therapy and drug screening transforms chemotherapy approaches.[3] Global
21st century Multimodal therapy Increasing integration of chemotherapy with radiotherapy and immunotherapy in combined treatment strategies. [6] Global
21st century Technology Integration of nanotechnology in chemotherapy enables co-delivery of drugs, controlled release, and improved targeting. [6] Global
21st century Clinical practice Use of chemotherapy in advanced cancers such as pancreatic cancer through monotherapy and combination regimens in clinical trials. [6] Global
21st century Innovation Development of new multidrug combinations and optimization of administration strategies to improve therapeutic outcomes and reduce toxicity. [6] Global
21st century Preclinical research Emergence of novel combination strategies demonstrating improved outcomes, including reversal of drug resistance in experimental models. [6] Global
2003 Drug approval Gefitinib (targeted inhibitor) and Cetuximab (monoclonal antibody) are approved for cancer treatment.[5] United States
2004 Drug approval Bevacizumab, an anti-angiogenic targeted therapy, is approved for multiple cancers including lung, kidney, and ovarian cancer.[5] United States

Meta information on the timeline

How the timeline was built

The initial version of the timeline was written by Sebastian.

Funding information for this timeline is available.

Feedback and comments

Feedback for the timeline can be provided at the following places:

  • FIXME

What the timeline is still missing

Timeline update strategy

See also

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 Mandal, Ananya (2023-06-23). "History of Chemotherapy". News-Medical. Retrieved 2026-04-08.
  2. ↑ 2.0 2.1 2.2 2.3 2.4 2.5 DeVita, Vincent T. Jr.; Chu, Edward (1 November 2008). "A history of cancer chemotherapy". Cancer Research. 68 (21): 8643–8653. doi:10.1158/0008-5472.CAN-07-6611. PMID 18974103.
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 3.17 3.18 3.19 3.20 3.21 DeVita, Vincent T. Jr.; Chu, Edward (1 November 2008). "A History of Cancer Chemotherapy". Cancer Research. 68 (21). American Association for Cancer Research: 8643–8653. doi:10.1158/0008-5472.CAN-07-6611.
  4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 Radhakrishnan, Jayant (2025-07-31). "The history of chemotherapy". Hektoen International. Retrieved 2026-04-08.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 5.13 "The history of chemotherapy". Onkologik. 2024-01-30. Retrieved 2026-04-08.
  6. ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 "Patient History of Chemotherapy". ScienceDirect. Elsevier. Retrieved 9 April 2026.
  7. ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 7.10 7.11 7.12 7.13 7.14 7.15 7.16 DeVita Jr., Vincent T.; Chu, Edward (2008-11-01). "A History of Cancer Chemotherapy". Cancer Research. 68 (21): 8643–8653. doi:10.1158/0008-5472.CAN-07-6611. Retrieved 2026-04-08.
  8. ↑ Buzdar, A.U.; Hortobagyi, G.N.; Kau, S.-W. (1990). "Doxorubicin-containing adjuvant therapy for patients with stage II breast cancer". Adjuvant therapy of cancer VI. Philadelphia: W.B. Saunders. pp. 210–215.
  9. ↑ Bonadonna, G.; Valagussa, P. (1985). "Adjuvant systemic therapy for breast cancer". Journal of Clinical Oncology. 3: 259–275.
  10. ↑ Bonadonna, G.; Brusamolino, E.; Valagussa, P. (1976). "Combination chemotherapy as an adjuvant treatment in operable breast cancer". New England Journal of Medicine. 294: 405–410.
  11. ↑ Greco, F.A.; Richardson, R.L.; Schulman, S.F. (1978). "Treatment of oat cell carcinoma of lung: complete remissions, acceptable complications, and improved survival". British Medical Journal. 2: 10–11.
  12. ↑ Matelski, H.W.; Lokich, J.J.; Huberman, M.S. (1984). "Adriamycin, cyclophosphamide, and etoposide in extensive stage small lung cancer". American Journal of Clinical Oncology. 7: 729–732.
  13. ↑ Rooney, M.; Kish, J.; Jacobs, J. (1985). "Improved complete response rate and survival in advanced head and neck cancer after three-course neoadjuvant chemotherapy with 120-hour 5-FU infusion and cisplatin". Cancer. 55: 1123–1128.
  14. ↑ Klein, H.O.; Wickramanayake, P.D.; Farrokh, G.-R. (1986). "5-fluorouracil, Adriamycin, and methotrexate: a combination protocol (FAMTX) for treatment of metastasized stomach cancer". Proceedings of the American Society of Clinical Oncology. 5: 84.
  15. ↑ Oster, M.W.; Gray, R.; Panasci, L. (1986). "Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, Adriamycin, and mitomycin, with 5-fluorouracil, streptozotocin, and mitomycin". Cancer. 57: 29–33.
  16. ↑ Jones, R.B.; Holland, J.F.; Bhardwaj, S. (1987). "A phase II study of intensive-dose Adriamycin for advanced breast cancer". Journal of Clinical Oncology. 5: 172–177.
  17. ↑ Fisher, B.; Redmond, C.; Wickerham, D.L. (1989). "Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel Project experience". Journal of Clinical Oncology. 7: 572–582.
  18. ↑ Preusser, P.; Wilke, H.; Achternath, W. (1989). "Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer". Journal of Clinical Oncology. 7: 1310–1317.
  19. ↑ Wilke, H.; Preusser, P.; Fink, U. (1990). "New developments in the treatment of gastric carcinoma". Seminars in Oncology. 17: 61–70.
  20. ↑ Foon, K.A.; Rai, K.R.; Gale, R.P. (1990). "Chronic lymphocytic leukemia: new insights into biology and therapy". Annals of Internal Medicine. 113: 525–539.
  21. ↑ Ihde, D.C.; Minna, J.D. (1991). "Non-small cell lung cancer. Part II: treatment". Current Problems in Cancer. 15: 105–154.
  22. ↑ Johnson, D.H. (1990). "Chemotherapy for unresectable non-small cell lung cancer". Seminars in Oncology. 17: 20–29.
  23. ↑ Levin, V.A.; Silver, P.; Hannigan, J. (1990). "Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine over BCNU for anaplastic gliomas". International Journal of Radiation Oncology Biology Physics. 18: 321–324.
  24. ↑ Moertel, C.G.; Fleming, T.R.; Macdonald, J.S. (1990). "Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma". New England Journal of Medicine. 322: 352–358.
  25. ↑ Berman, E.; Heller, G.; Santorsa, J. (1991). "Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia". Blood. 77: 1666–1674.
  26. ↑ Murray, N.; Shah, A.; Osoba, D. (1991). "Intensive weekly chemotherapy for the treatment of extensive stage small cell lung cancer". Journal of Clinical Oncology. 9: 1632–1638.
  27. ↑ Jones, S.E.; Mennel, R.G.; Brooks, B. (1991). "Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer". Journal of Clinical Oncology. 19: 1736–1739.
  28. ↑ Linker, C.A.; Levitt, L.J.; O'Donnell, M. (1991). "Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report". Blood. 78: 2814–2822.
  29. ↑ Ajani, J.A.; Ota, D.M.; Jackson, D.E. (1991). "Current strategies in the management of locoregional and metastatic gastric carcinoma". Cancer. 67: 260–265.
  30. ↑ Tanum, G.; Tveit, K.; Karlsen, K.O. (1991). "Chemotherapy and radiation therapy for anal carcinoma: survival and late morbidity". Cancer. 67: 2462–2466.
  31. ↑ DeCaprio, J.A.; Mayer, R.J.; Gonin, R. (1991). "Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial". Journal of Clinical Oncology. 9: 2128–2133.
  32. ↑ Fukuoka, M.; Furuse, K.; Saijo, N. (1991). "Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer". Journal of the National Cancer Institute. 83: 855–861.
  33. ↑ Roth, B.J.; Johnson, D.H.; Einhorn, L.H. (1992). "Randomized study of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these two agents in extensive small cell lung cancer". Journal of Clinical Oncology. 10: 282–291.
  34. ↑ Herskovic, A.; Martz, K.; Al-Sarraf, M. (1992). "Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus". New England Journal of Medicine. 326: 1593–1598.
  35. ↑ Saven, A.; Piro, L.D. (1992). "Treatment of hairy cell leukemia". Blood. 79: 1111–1120.
  36. ↑ Rougier, P.; Laplanche, A.; Huguier, M. (1992). "Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial". Journal of Clinical Oncology. 10: 1112–1118.
  37. ↑ Forastiere, A.A.; Orringer, M.B.; Perez-Tamayo, C. (1993). "Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report". Journal of Clinical Oncology. 11: 1118–1123.
  38. ↑ Hehlmann, R.; Heimpel, H.; Hasford, J. (1993). "Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea". Blood. 82: 398–407.
  39. ↑ Keating, M.J.; O'Brien, S.; Kantarjian, H. (1993). "Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent". Blood. 81: 2878–2884.
  40. ↑ O'Brien, S.; Kantarjian, H.; Beran, M. (1993). "Results of fludarabine and prednisone therapy in chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment". Blood. 82: 1695–1700.
  41. ↑ Le Chevalier, T.; Brisgand, D.; Douillard, J.-Y. (1993). "Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer". Journal of Clinical Oncology. 12: 360–367.
  42. ↑ Keane, M.; Carney, D.N. (1993). "Treatment of elderly patients with small cell lung cancer". Lung Cancer. 9: S91 – S98.
  43. ↑ Grunberg, S.M.; Crowley, J.; Livingston, R. (1993). "Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study". Journal of Clinical Oncology. 11: 1598–1601.
  44. ↑ Grossman, S.A.; Wharam, M.; Sheidler, V. (1992). "BCNU/cisplatin followed by radiation in high-grade astrocytomas". Proceedings of the American Society of Clinical Oncology. 11: 149.
  45. ↑ Gilbert, M.R.; Lunsford, L.D.; Kondziolka, D. (1993). "Phase II trial of continuous infusion chemotherapy and radiotherapy for malignant gliomas". Proceedings of the American Society of Clinical Oncology. 12: 176.
  46. ↑ Hortobagyi, G.N. (1992). "Treatment of locally advanced breast cancer". Seminars in Oncology. 19: 278–285.
  47. ↑ Hortobagyi, G.N.; Ames, F.C.; Buzdar, A.U. (1988). "Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy". Cancer. 62: 2507–2516.
  48. ↑ Moliterni, A.; Bonadonna, G.; Valagussa, P. (1991). "Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer". Journal of Clinical Oncology. 9: 1124–1130.
  49. ↑ Brandes, A.; Soesan, M.; Fiorentino, M.V. (1991). "Medical treatment of high grade malignant gliomas in adults: an overview". Anticancer Research. 11: 719–728.
  50. ↑ Deutsch, M.; Green, S.B.; Strike, T.A. (1989). "Results of a randomized trial comparing BCNU plus radiotherapy and other regimens in malignant glioma". International Journal of Radiation Oncology Biology Physics. 16: 1389–1396.
  51. ↑ Levin, V.A.; Silver, P.; Hannigan, J. (1990). "Superiority of adjuvant chemotherapy with CCNU, procarbazine, and vincristine over BCNU for anaplastic gliomas". International Journal of Radiation Oncology Biology Physics. 18: 321–324.
  52. ↑ Le Chevalier, T.; Pujol, J.L.; Douillard, J.Y. (1994). "A three-arm trial of vinorelbine plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in advanced non-small cell lung cancer: an expanded analysis". Seminars in Oncology. 21: 28–34.
  53. ↑ Rosell, R.; Gomez-Codina, J.; Camps, C. (1994). "A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer". New England Journal of Medicine. 330: 153–158.
  54. ↑ O'Connell, M.J.; Martenson, J.A.; Wieand, H.S. (1994). "Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery". New England Journal of Medicine. 331: 502–507.
  55. ↑ Buzdar, A.U.; Hortobagyi, G.N.; Kau, S.-W. (1990). "Doxorubicin-containing adjuvant therapy for patients with stage II breast cancer". Adjuvant therapy of cancer VI. Philadelphia: W.B. Saunders. pp. 210–215.
  56. ↑ Ajani, J.A. (1994). "Contributions of chemotherapy in the treatment of carcinoma of the esophagus: results and commentary". Seminars in Oncology. 21: 474–482.
  57. ↑ Hehlmann, R.; Heimpel, H.; Hasford, J. (1994). "Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia". Blood. 84: 4064–4077.
  58. ↑ Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994). "Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia". New England Journal of Medicine. 330: 820–825.
  59. ↑ Buroker, T.R.; O'Connell, M.J.; Wieand, H.S. (1994). "Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer". Journal of Clinical Oncology. 12: 14–20.
  60. ↑ O'Connell, M.J.; Martenson, J.A.; Wieand, H.S. (1994). "Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery". New England Journal of Medicine. 331: 502–507.
  61. ↑ Erlichman, C.; Marsoni, S.; Seitz, J. (1994). "Event free and overall survival is increased by FUFA in resected B and C colon cancer: a prospective pooled analysis of 3 randomized trials". Proc Am Soc Clin Oncol (abstract). 13: 194.
  62. ↑ Sandler, A.; Loehrer, P.J.; Ansari, R. (1994). "A phase III study of VP16 plus cisplatin alone or with ifosfamide in previously untreated extensive small cell lung cancer". Lung Cancer. 11: 242.
  63. ↑ Einhorn, L.H.; Loehrer, P.J. (1995). "Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer". Seminars in Oncology. 22: 28–31.
  64. ↑ Bonadonna, G.; Zambetti, M.; Valagussa, P. (1995). "Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results". JAMA. 273: 542–547.
  65. ↑ Choy, H.; Safran, H. (1995). "Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer". Seminars in Oncology. 22: 55–57.
  66. ↑ Langer, C.J.; Leighton, J.C.; Comis, R.L. (1995). "Paclitaxel by 24-hour or 1-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience". Seminars in Oncology. 22: 18–29.
  67. ↑ Gianni, L.; Munzone, E.; Capri, G. (1995). "Paclitaxel by 3-hour infusion with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects". Journal of Clinical Oncology. 13: 2688–2699.
  68. ↑ Evans, W.K.; Stewart, D.J.; Tomiak, E. (1995). "Carboplatin and paclitaxel by 1-hour infusion for advanced non-small cell lung cancer". Proceedings of the American Society of Clinical Oncology. 14: 374.
  69. ↑ Rowinsky, E.K.; Sartorius, S.E.; Bowling, M.K. (1995). "Paclitaxel on a 3-hour schedule and carboplatin in non-small cell lung cancer: feasibility of maximally tolerated combination doses". Proceedings of the American Society of Clinical Oncology. 14: 354.
  70. ↑ Hainsworth, J.D.; McKay, C.F.; Miller, P.S. (1995). "Treatment of small cell lung cancer with paclitaxel (one-hour infusion), carboplatin, and low-dose daily etoposide". Proceedings of the American Society of Clinical Oncology. 14: 384.
  71. ↑ Faylona, E.A.; Loehrer, P.J.; Ansari, R. (1995). "Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group trial". Journal of Clinical Oncology. 13: 1209–1214.
  72. ↑ Forastiere, A.A.; Urba, S.G. (1995). "Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer". Seminars in Oncology. 22: 24–27.
  73. ↑ Fenaux, P.; Chastang, C.; Chomienne, C. (1995). "Treatment of newly diagnosed acute promyelocytic leukemia by all transretinoic acid combined with chemotherapy: the European experience". Leukemia & Lymphoma. 16: 431–437.
  74. ↑ Gianni, L.; Munzone, E.; Capri, G. (1995). "Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines". Journal of the National Cancer Institute. 87: 1169–1175.
  75. ↑ Hainsworth, J.D.; Stroup, S.L.; Spigel, S.C. (1995). "Treatment of locally advanced, unresectable non-small cell lung cancer with paclitaxel, cisplatin, etoposide, and radiation therapy". Proceedings of the American Society of Clinical Oncology. 14: 383.
Retrieved from "https://timelines.issarice.com/index.php?title=Timeline_of_chemotherapy&oldid=90144"